Effect of odanacatib on bone turnover markers, bone density and geometry of the spine and hip of ovariectomized monkeys: A head-to-head comparison with alendronate

Bone

Volumn 56, Issue 2, 2013, Pages 489-496

  Williams, Donald S ^a   McCracken, Paul J ^a,d   Purcell, Mona ^a   Pickarski, Maureen ^a   Mathers, Parker D ^a   Savitz, Alan T ^a   Szumiloski, John ^a   Jayakar, Richa Y ^a   Somayajula, Sangeetha ^a   Krause, Stephen ^a   Brown, Keenan ^b   Winkelmann, Christopher T ^a   Scott, Boyd B ^a   Cook, Lynn ^a   Motzel, Sherri L ^a   Hargreaves, Richard ^a   Evelhoch, Jeffrey L ^a   Cabal, Antonio ^a   Dardzinski, Bernard J ^a,e   Hangartner, Thomas N ^c   Duong, Le T ^a   more..

^a MERCK RESEARCH LABORATORIES   (United States)

^b Mindways Software   (United States)

^c Wright State University   (United States)

^d EISAI INC   (United States)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Bone turnover marker; Cathepsin K inhibitor; Odanacatib

Indexed keywords

ALENDRONIC ACID; ALKALINE PHOSPHATASE BONE ISOENZYME; AMINO TERMINAL TELOPEPTIDE; CARBOXY TERMINAL TELOPEPTIDE; ODANACATIB;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BONE DENSITY; BONE MINERAL; BONE TURNOVER; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CORTICAL THICKNESS (BONE); DRUG EFFICACY; DRUG EXPOSURE; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FEMUR NECK; GEOMETRY; HAPLORHINI; HIP; LUMBAR SPINE; NONHUMAN; OSTEOLYSIS; OVARIECTOMY; RHESUS MONKEY;

BONE TURNOVER MARKER; CATHEPSIN K INHIBITOR; ODANACATIB;

ALENDRONATE; ANIMALS; BIPHENYL COMPOUNDS; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; BONE REMODELING; FEMALE; HAPLORHINI; HIP JOINT; OVARIECTOMY; SPINE;

EID: 84882737244     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2013.06.008     Document Type: Article

References (24)

1. Cusick T., Chen C.M., Pennypacker B.L., Pickarski M., Kimmel D.B., Scott B.B., et al. Odanacatib treatment increases hip bone mass and cortical thickness by preserving endocortical bone formation and stimulating periosteal bone formation in the ovariectomized adult rhesus monkey. J Bone Miner Res 2012, 27(1; 21):524-537.
2. Masarachia P.J., Pennypacker B.L., Pickarski M., Scott K.R., Wesolowski G.A., Smith S.Y., et al. Odanacatib reduces bone turnover and increases bone mass in the lumbar spine of skeletally mature ovariectomized rhesus monkeys. J Bone Miner Res 2012, 27(2; 19):509-523.
3. Jayakar R.Y., Cabal A., Szumiloski J., Sardesai S., Phillips E.A., Laib A., et al. Evaluation of high-resolution peripheral quantitative computed tomography, finite element analysis and biomechanical testing in a pre-clinical model of osteoporosis: a study with odanacatib treatment in the ovariectomized adult rhesus monkey. Bone 2012, 50(1):1379-1388.
4. Cusick T., Pennypacker B., Pickarski M., Samadfam R., Duong L.T. Differential effects of odanacatib and alendronate on bone turnover in the femoral neck of adult ovariectomized rhesus monkeys. Bone 2012, 50:S159.
5. Lin J.H. Bisphosphonates: a review of their pharmacokinetic properties. Bone 1996, 18(1):75-85.
6. Balena R., Toolan B.C., Shea M., Markatos A., Myers E.R., Lee S.C., et al. The effects of 2-year treatment with the aminobisphosphonate alendronate on bone metabolism, bone histomorphometry, and bone strength in ovariectomized nonhuman primates. J Clin Invest 1993, 92(43):2577-2586.
7. Poole K.E., Mayhew P.M., Rose C.M., Brown J.K., Bearcroft P.J., Loveridge N., et al. Changing structure of the femoral neck across the adult female lifespan. J Bone Miner Res 2010, 25(1):482-491.
8. Pinheiro J.C., Bates D.M. Mixed effects models in S and S-PLUS 2000, Springer, New York, NY, USA.
9. A language and environment for statistical computing 2010, R Foundation for statistical computing, Vienna, Austria.
10. Bouxsein M.L., Seeman E. Quantifying the material and structural determinants of bone strength. Best Pract Res Clin Rheumatol 2009, 23(1):741-753.
11. Griffith J.F., Engelke K., Genant H.K. Looking beyond bone mineral density: imaging assessment of bone quality. Ann N Y Acad Sci 2010, 1192(1):45-56.
12. Nishiyama K.K., Boyd S.K. In vivo assessment of trabecular and cortical bone microstructure. Clin Calcium 2011, 21(3):1011-1019.
13. Roberts B.J., Thrall E., Muller J.A., Bouxsein M.L. Comparison of hip fracture risk prediction by femoral aBMD to experimentally measured factor of risk. Bone 2010, 46(1):742-746.
14. Varghese B.A., Miller M.E., Hangartner T.N. Estimation of bone strength from pediatric radiographs of the forearm. J Musculoskelet Neuronal Interact 2008, 8(3):379-390.
15. Stroup G., Kumar S., Jerome C. Treatment with a potent cathepsin K inhibitor preserves cortical and trabecular bone mass in ovariectomized monkeys. Calcif Tissue Int 2009, 85:344-355.
16. Bone H.G., McClung M.R., Roux C., Recker R.R., Eisman J.A., Verbruggen N., et al. Odanacatib, a cathepsin-K inhibitor for osteoporosis: a two-year study in postmenopausal women with low bone density. J Bone Miner Res 2010, 25(1; 10):937-947.
17. Langdahl B., Binkley N., Bone H., Gilchrist N., Resch H., Rodriguez P.J., et al. Odanacatib in the treatment of postmenopausal women with low bone mineral density: five years of continued therapy in a phase 2 study. J Bone Miner Res 2012, 27(1):2251-2258.
18. Chesnut C.H., McClung M.R., Ensrud K.E., Bell N.H., Genant H.K., Harris S.T., et al. Alendronate treatment of the postmenopausal osteoporotic woman: effect of multiple dosages on bone mass and bone remodeling. Am J Med 1995, 99(1):144-152.
19. McClung M.R., Wasnich R.D., Hosking D.J., Christiansen C., Ravn P., Wu M., et al. Prevention of postmenopausal bone loss: six-year results from the Early Postmenopausal Intervention Cohort Study. J Clin Endocrinol Metab 2004, 89(1):4879-4885.
20. Harris S.T., Watts N.B., Genant H.K., McKeever C.D., Hangartner T., Keller M., et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 1999, 282(8):1344-1352.
21. Miller P.D., Recker R.R., Reginster J.Y., Riis B.J., Czerwinski E., Masanauskaite D., et al. Efficacy of monthly oral ibandronate is sustained over 5years: the MOBILE long-term extension study. Osteoporos Int 2012, 23(1):1747-1756.
22. Cabal A., Sardesai S., Phillips E.A., Jayakar R.Y., McCracken P.J., Szumiloski J., et al. HRpQCT based finite element analysis estimates of bone strength at ultra-distal radius in ovariectomized rhesus monkeys demonstrates efficacy of odanacatib and differentiation from alendronate. Bone 2011, 48:S93-S94.
23. McCracken P.J., Jayakar R.Y., Purcell M.L., Mathers P., Savitz A., Szumiloski J., et al. A multi-modality imaging comparison of odanacatib to alendronate in the ovariectomized rhesus monkey. J Bone Miner Res 2012, 25(Suppl. 1).
24. Somayajula S., Fayad G., Crawford R., Kummari S.R., Dogdas B., Purcell M.L., et al. Comparing treatment effects of odanacatib and alendronate in lumbar vertebrae of ovariectomized rhesus monkeys using quantitative computed tomography. J Bone Miner Res 2012, 27(Suppl. 1).